CLAIM AMENDMENTS

1. (Currently Amended) A composition comprising a T lymphocyte having (i) a recombinant chimeric receptor or a recombinant T-cell receptor, either of which is reactive with a tumor antigen, and (ii) an endogenous T-cell receptor reactive with a cell, which cell is allogeneic to the T lymphocyte.

2. (Cancelled)

3. (Cancelled)

4. (Previously Presented) The composition of claim 1, wherein the tumor antigen is an ovarian tumor antigen.

5. (Cancelled)

6. (Cancelled)

7. (Previously Presented) The composition of claim 1, wherein the chimeric receptor comprises a single chain Fv receptor.

8. (Previously Presented) The composition of claim 1, wherein the cell is a peripheral blood mononuclear cell.

9. (Cancelled)

10. (Currently Amended) The composition of claim 4, wherein the recombinant chimeric receptor is Mov-γ.

11. (Currently Amended) A lymphocyte having a T-cell receptor reactive with a cell, which cell is allogeneic to the lymphocyte, and a chimeric receptor reactive with a tumor antigen.

12.-39. (Cancelled)

40. (Currently Amended) A pharmaceutical composition comprising:

a T lymphocyte containing a recombinant chimeric receptor reactive with a tumor antigen and an endogenous T-cell receptor reactive with a cell, which cell is allogeneic to the T lymphocyte; and

a pharmaceutically acceptable carrier.

41. (Currently Amended) A method of preparing lymphocytes having dual ~~antigen~~ specificity comprising:

contacting lymphocytes with a cell, which cell is allogeneic to the lymphocytes; and

transducing the lymphocytes with a chimeric receptor gene, said gene encoding a chimeric receptor, which is reactive with a tumor antigen.

42.-43. (Cancelled)

44. (Previously Presented) The composition of claim 4, wherein the ovarian tumor antigen is folate binding protein (FBP).

45. (Currently Amended) The composition of claim 1, wherein the T lymphocyte is a human T lymphocyte.

46. (Currently Amended) The composition of claim 1, wherein the cell is a splenocyte, ~~or~~ a dendritic cell, or a B cell.

47. (Previously Presented) The lymphocyte of claim 11, wherein the lymphocyte is a human lymphocyte.

48. (Previously Presented) The lymphocyte of claim 11, wherein the tumor antigen is an ovarian tumor antigen.

49. (Previously Presented) The lymphocyte of claim 48, wherein the ovarian tumor antigen is FBP.

50. (Currently Amended) The lymphocyte of claim 11, wherein the cell is a peripheral blood mononuclear cell, ~~or~~ a splenocyte, or a B cell.

51. (Previously Presented) The lymphocyte of claim 11, wherein the chimeric receptor is Mov-γ.

52. (Currently Amended) The pharmaceutical composition of claim 40, wherein the T lymphocyte is a human T lymphocyte.

53. (Previously Presented) The pharmaceutical composition of claim 40, wherein the chimeric receptor is Mov-γ.

54. (Previously Presented) The pharmaceutical composition of claim 40, wherein the tumor antigen is an ovarian tumor antigen.

55. (Previously Presented) The pharmaceutical composition of claim 53, wherein the ovarian tumor antigen is FBP.

56. (Currently Amended) The pharmaceutical composition of claim 40, wherein the cell is a peripheral blood monuclear cell, a splenocyte, ~~or~~ a dendritic cell, or a B cell.

57. (Previously Presented) The method of claim 41, wherein the chimeric receptor is Mov-γ.

58. (Previously Presented) The method of claim 41, wherein the cell is a peripheral blood mononuclear cell, a splenocyte, ~~or~~ a dendritic cell, or a B cell.

59. (Previously Presented) The method of claim 41, wherein the tumor antigen is an ovarian tumor antigen.

60. (Previously Presented) The method of claim 59, wherein the ovarian tumor antigen is FBP.

61. (Previously Presented) The method of claim 41, wherein the lymphocytes are human lymphocytes.

62.-70. (Cancelled)

71. (New) The lymphocytes prepared by the method of claim 41.